How has been the historical performance of Hamps Bio?

Answer:The historical performance of Hamps Bio shows a mixed trend in its financial metrics over the past three years.

Breakdown:
Hamps Bio's net sales have increased from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, indicating a steady growth in revenue. However, the total operating income has also risen correspondingly, reflecting no other operating income. The total expenditure, excluding depreciation, has grown from 4.71 Cr in Mar'23 to 5.90 Cr in Mar'25, driven by higher raw material costs and employee expenses. Operating profit (PBDIT) has fluctuated, peaking at 1.21 Cr in Mar'24 before dropping to 0.92 Cr in Mar'25. Profit before tax has similarly decreased from 0.65 Cr in Mar'24 to 0.40 Cr in Mar'25, while profit after tax has fallen from 0.50 Cr to 0.30 Cr in the same period. The earnings per share have also declined from 2.40 in Mar'23 to 0.34 in Mar'25. On the balance sheet, total assets have increased significantly from 3.61 Cr in Mar'22 to 12.67 Cr in Mar'25, with total liabilities rising from 3.61 Cr to 12.67 Cr as well, indicating a growing leverage. The book value per share has improved from 4.19 in Mar'22 to 20.20 in Mar'25, suggesting enhanced shareholder value despite the declining profitability metrics. Cash flow from operating activities has remained stagnant, with no cash inflow reported in the last three years.